ChemicalBook > Product Catalog >API >Antineoplastic agents >Hormonal antineoplastic drugs >Letrozole

Letrozole

Letrozole Suppliers list
Company Name: Shenzhen Sendi Biotechnology Co.Ltd.
Tel: 0755-23311925 18102838259
Email: Abel@chembj.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:99% Package:5500/KG
Company Name: Hebei Jiangkai Trading Co., Ltd
Tel: 0086-17197824289/17197824028
Email: catherine@tuskwei.com
Products Intro: Product Name:Letrozole;Femara
CAS:112809-51-5
Purity:99.67% Package:In Aluminium Foil Packing
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: CAS:112809-51-5
Purity:99% Package:500G;1KG;5KG;25KG
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Email: sales@mainchem.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Company Name: PI & PI BIOTECH INC.
Tel: 020-81716320
Email: Sales@pipitech.com
Products Intro: Product Name:Letrozole
CAS:112809-51-5
Purity:90%+ Package:10mg, 25mg, 50mg, 100mg, Other scale please email Sales@pipitech.com
Letrozole Basic information
Indications and uses Side effects
Product Name:Letrozole
Synonyms:LetrozoleUsp28;Letrozole99%;CGS-20267, Femara;LETRAZOLE;letrozolex;Lelrozol;1-[BIS(4-CYANOPHENYL)METHYL]-1,2,4-TRIAZOLE;4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile
CAS:112809-51-5
MF:C17H11N5
MW:285.3
EINECS:1806241-263-5
Product Categories:Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles;ELOXATIN;Anti-cancer&immunity
Mol File:112809-51-5.mol
Letrozole Structure
Letrozole Chemical Properties
Melting point 181-183°C
storage temp. -20°C Freezer
solubility DMSO: >50mg/mL
color white to off-white
Merck 14,5450
InChIKeyHPJKCIUCZWXJDR-UHFFFAOYSA-N
CAS DataBase Reference112809-51-5(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 36/37/38
Safety Statements 26-36
RTECS DI4957000
Hazardous Substances Data112809-51-5(Hazardous Substances Data)
MSDS Information
Letrozole Usage And Synthesis
Indications and usesLetrozole is part of a new generation of highly selective aromatase inhibitors and is an artificially synthesized benzotriazole derivative. Letrozole inhibits aromatase to lower estrogen levels, thus preventing estrogen from stimulating tumor growth. Its in vivo activity is 150-250 times stronger than that of first generation aromatase inhibitor Amarante. As it is highly selective, it will not impact glucocorticoid, mineralocorticoid and thyroid functions; even at high dosages, it will not have any inhibiting effects on adrenal corticosteroid secretion, giving it a high treatment index. Letrozole has no latent toxicity towards any bodily systems and target organs, has no mutagenicity and carcinogenic effects, has minimal toxic side effects, is well-tolerated, and has stronger anticancer effects than other aromatase inhibitors and antiestrogen drugs. Letrozole is suitable for advanced breast cancer postmenopausal patients who have not responded to estrogen-suppressing treatment and for early breast cancer treatment. It is used to treat postmenopausal patients with advanced breast cancer and serves as a second-line treatment to follow unsuccessful antiestrogen treatment. Compared to the current standard Tamoxifen treatment, Letrozole can better prevent the risk of breast cancer recurrence.
Side effectsRandomized grouping studies have shown that daily oral ingestion of 2.5mg Letrozole leads to a 33% rate of drug-related negative reactions, a percentage much lower than AG group’s 46%. Negative reactions to Letrozole are mostly mild or moderate, consisting mostly of nausea (2-9%), headache (0-7%), bone pain (4-10%), hot flashes (0-9%) and weight gain (2-8%). Other uncommon side effects include constipation, diarrhea, itching, rash, joint pain, chest pain, abdominal pain, fatigue, insomnia, dizziness, edema, high blood pressure, arrhythmia, thrombosis, dyspnea, vaginal bleeding, etc.
DescriptionLetrozole (trade name: Femara) is an orally active nonsteroidal aromatase inhibitor. As a competitive inhibitor of the aromatase, Letrozole inhibits the conversion of androgens to estrogen (estrogen stimulates breast tissues and breast cancer reoccurrence) and gonadal steroidogenesis. It can be used for the treatment of breast cancer that is hormonally-responsive or has an unknown receptor status in postmenopausal women. Besides this, Letrozole also has some off-label use such as ovarian stimulation, pretreatment of termination of pregnancy, treatment of gynecomastia, treatment of endometriosis, and promoting spermatogenesis for male patients of nonobstructive azoospermia.
Chemical Propertieswhite to light yellow crystal
UsesA nonsteroidal aromatase inhibitor structurally related to Fadrozole. Antineoplastic
Referenceshttps://www.drugbank.ca/drugs/DB01006
https://en.wikipedia.org/wiki/Letrozole
Letrozole Preparation Products And Raw materials
Raw materialsPotassium tert-butanolate-->3-Amino-5-mercapto-1,2,4-triazole-->4-Cyanobenzyl bromide
Tag:Letrozole(112809-51-5) Related Product Information
[1-Hydroxy-3-(methylpentylamino)-propylidene]bisphosphonic acid sodium salt Irinotecan hydrochloride trihydrate 4,4''-DICYANOBENZOPHENONE(INTERMEDIATE OF LETROZOLE ) 4-[α-(4-Cyanophenyl)-hydroxymethyl]-benzonitrile ( For Letrozole ) 5-Methyl-1,3-benzenediacetonitrile 4-BENZYLBENZONITRILE 4,4'-(1-METHYLENE) BIS-BENZONITRILE 1-BENZHYDRYL-1,2,4-TRIAZOLE (S)-1-(4-CYANOPHENYL)ETHANAMINE 1,1-bis(4-methylphenyl)methanamine (R)-1-(4-CYANOPHENYL)ETHANAMINE 4-((1H-1,2,4-triazol-1-yl)methyl)benzonitrile (intermediate of letrozole),INTERMEDIATE OF LETROZOLE,4-[1-(1,2,4-triazolyl)-methyl]-benzonitrile ( For Letrozole ) 4-Cyanobenzylamine Letrozole 5-Methyl-1H-benzotriazole Chlorodimethylphenylsilane Tolyltriazole 1,2,4-Triazole